Advertisement

Topics

Sirnaomics to Start US Trial of siRNA Treatment for Bile Duct Cancer

04:41 EDT 17 Aug 2018 | ChinaBio Today

Sirnaomics of Maryland was approved to start US trials of its anti-cancer/anti-fibrosis siRNA (small interfering RNA) therapeutic in patients with advanced cholangiocarcinoma (CCA). Sirnaomics has facilities in Suzhou and Guangzhou. STP705 works by silencing both TGF-β1 and COX-2 gene expression within the liver. CCA is the second most common hepatic primary malignancy and more common in Asia than the west. It is also known as bile duct adenocarcinoma and biliary tract cancer. Five-year survival ranges from 2-30%. More details....

Share this with colleagues:

Original Article: Sirnaomics to Start US Trial of siRNA Treatment for Bile Duct Cancer

NEXT ARTICLE

More From BioPortfolio on "Sirnaomics to Start US Trial of siRNA Treatment for Bile Duct Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gene Expression
The process of gene expression is used by eukaryotes, prokaryotes, and viruses to generate the macromolecular machinery for life. Steps in the gene expression process may be modulated, including the transcription, RNA splicing, translation, and post-tran...